Bacteremic Group A Streptococcal Co-Infection in Two Adults with H3N2 Influenza in Japan, 2025–2026: A Case Series Authors: Masafumi Seki Published: 2026 ABSTRACT AbstractTwo adult cases of influenza with bacteremia due to Group A Streptococcus pyogenes (GAS) in the 2025–2026 season, which was a major season of H3N2 subclade (subclade K) type influenza in Japan, are presented. Case 1: A 52-year-old man with no underlying diseases and no vaccination history was admitted as influenza A. The onset was five days ago, and GAS was isolated from his blood. He was in shock with lobular pneumonia, high inflammation, and renal dysfunction, and finally he died although intensive care and appropriate antiviral/antibiotic treatment. Case 2: A 68-year-old woman with no underlying disease was admitted as influenza A. She received laninamivir inhalation on Day −1 and had history of the influenza vaccine for the season. She was also in shock and renal dysfunction status but did not show obvious pneumonia although Streptococcus pneumoniae (S. pneumoniae) was isolated from her sputum. In addition, GAS was also isolated from her blood on admission. She finally recovered by intensive care and appropriate antibiotic treatment. Both patients showed septic status and acute kidney injury (AKI) on admission; however, one patient survived and the other did not. These cases highlight the severity of influenza–GAS co-infection during a season in which H3N2 subclade K predominated. Early antiviral treatment within 48 hours, vaccination, and high index of suspicion for invasive GAS in influenza patients with shock will be needed.Keywords: acute kidney injury, bacteremia, co-infection, Influenza, Streptococcus pyogenes, subclade K Introduction The influenza virus induces acute febrile illness, malaise, and respiratory failure, and influenza is frequently lethal in elderly patients and/or patients with underlying diseases when the patients develop pneumonia, encephalopathy, or myocarditis.1,2 In Japan, there have been influenza outbreaks in hospitals and nursing homes in winter, and usually several patients are isolated in private rooms and receive drug therapy with anti-influenza agents, including oseltamivir, laninamivir, and baroxavir.3–5 In addition, a prophylactic strategy involving vaccination has also been considered important, and annual influenza vaccinations are strongly recommended in the national immunization program for children and elderly people over 65 years of age. In the 2025–2026 season, a mutant strain of H3N2 influenza virus: J.2.4.1, so called “subclade K”, became dominant, and vaccine effectiveness was a concern.6,7 Influenza A(H3N2) subclade K dominated the start of the 2025–2026 season in the United Kingdom (UK). Post-infection ferret antisera raised against northern hemisphere 2025–2026 vaccine strains showed reduced reactivity to subclade K viruses in the UK, aligning with significant antigenic drift and World Health Organization (WHO) reports. In line with epidemiological observations from Australia, the UK, other European countries, and Japan, subclade K appears to have a transmission fitness advantage, and along with the prolonged season, there was an increased clinical burden. Furthermore, the number of reported cases of invasive Group A Streptococcus pyogenes (GAS) infectious disease in Japan in 2024 was 1888 cases, marking the highest total since records began in 1999 although Invasive GAS infections also increased substantially in 10 US states during a surveillance period from 2013 to 2022.8,9 Co-infection GAS and influenza may be promoted by pathogenic factors of influenza virus including PB1-F2 protein.10 In this report, the cases of two severe influenza patients during the subclade K-dominant period in Japan are presented and compared. Both patients showed co-infection with GAS as bacteremia, with septic status and acute kidney injury (AKI). One patient with pneumonia did not survive, but the other patient, who was older, survived although Streptococcus pneumoniae (S. pneumoniae) was also isolated. Patients and Methods Patients The two cases were the only adult GAS-bacteremia influenza co-infections cases among total five GAS-bacteremia patients seen at our institution this 2025–2026 season. We had a total of 36 adult hospitalized influenza patients in this season. Ethics This study was approved as `Analysis of predicted factors in severe COVID-19 and the other viral infected patients’ by the Institutional Review Board (IRB) of Saitama Medical University International Medical Center (Hidaka City, Saitama, Japan) on March 01, 2023 (Approved number: # No. 2022–146) and registered in UMIN (University hospital Medial Information Network, Tokyo, Japan) as UMIN000047691. The presented cases were collected according to this study in 2025–2026 season. Written, informed consent for publication of case details, such as background, physical examinations, laboratory data, and accompanying images were obtained from Patient 1’s next of kin and Patient 2. This was done accordance with the Declaration of Helsinki, the regulation of our hospital (Saitama Medical University International Medical Center) (Supplementary File 1). Influenza Diagnosis and Microbiology for Bacteria The influenza A diagnosis was based on the positive rapid influenza antigen test (ImmunoAce-Flu, Tauns, Shizuoka, Japan). We could not perform subtyping for subclade K by RT-PCR and/or sequencing through the National Institute of Infectious Diseases/WHO Collaborating Center). Blood specimens from adult patients were systematically collected and cultured using the BD BACTEC system (Franklin Lakes, NJ, USA), bioMérieux BacT/ALERT system (Marcy l’Etoile, France), and Oxoid Signal Blood Culture system (Newport, England), including both anaerobic and aerobic resins. Bottles containing 8–10 mL of whole blood were incubated in MIR-553 instruments (Sanyo, Tokyo, Japan) for 5–7 days for the standard incubation protocol or for fewer days if an earlier positive signal was detected. Direct identification of bacteria by MALDI-TOF MS from both positive aerobic and anaerobic bottles (Bruker Daltonics, Bremen, Germany) was performed. After subculturing on agar plates, any positive blood culture was simultaneously assessed for bacterial identification using conventional procedures, including MicroScan Walkaway panels (Beckman Coulter, Jersey City, NJ, USA). The minimum inhibitor concentrations (MICs) of isolated bacteria were determined by a Phenix M-50 system (Becton Dickinson, Franklin Lakes, NJ, USA) and Lysys@S4 (Shimazu Diagnostics, Tokyo, Japan) based on the broth microdilution method. The isolates were considered susceptible (S), intermediate (I), or resistant (R) according to Clinical and Laboratory Standards Institute (CLSI) criteria for minimum inhibitory concentration (MIC).11–13 We did not perform emm typing or superantigen gene profiling for invasive GAS. Case Definitions AKI, septic shock, and pneumonia were defined and diagnosed by KDIGO,14 Sepsis-3,15 and CT/clinical symptoms. Critically, streptococcal toxic shock syndrome was diagnosed according to CDC/Working Group case definition: hypotension + multi-organ involvement + isolation of GAS from a normally sterile site.16 Statistical Analysis Given the n = 2 design, no statistical comparisons were performed; data are presented descriptively. Case Series Patient 1 A 52-year-old man with no underlying diseases was admitted to our hospital with a fever (38.3°C) and dyspnea (SpO2 89% on room air) (Day 0) (Table 1). Dyspnea had developed five days earlier (Day −5), but he visited an outpatient clinic three days later (Day −3), and influenza A was diagnosed by a rapid antigen test. Oral administration of oseltamivir 75 mg twice per day for five days was started. He had not received the influenza vaccine for the season. Table 1Clinical Background Characteristics of the Two PatientsPatient 1Patient 2Age52 years old68 years oldMale/FemaleMaleFemaleUnderlying diseasesNoneNoneFlu VaccinationNonePositiveTreatment start from onset3 days1 dayAnti-influenza agentsOseltamivirLaninamivirPre-hospital antibioticsNoneNonePneumoniaLobar typeNoneOther bacteria (Sputum)NoneS. pneumoniaePrognosisNon-SurvivedSurvived Clinical Background Characteristics of the Two Patients On admission (Day 0), he was in shock, with blood pressure of 80/50 mmHg, and a norepinephrine drip infusion was started. His body temperature was 37.9°C, and quick SOFA score was 3/3 points. Chest radiography and computed tomography showed massive lobar pneumonia in the right lower lung field (Figure 1), and laboratory data showed very severe inflammation, including C-reactive protein (CRP) of 52.0 mg/dL and procalcitonin (PCT) >100 ng/mL, although his white blood cell (WBC) count was not increased (Table 2). In addition, serum creatinine (sCr) was significantly increased, at 6.47 mg/dL, suggesting acute kidney injury (AKI). Chest X-ray and computed tomography (CT) of Patient 1 on admission (Day 0). (A): Chest X-ray, and (B): CT. Arrows indicated the massive infiltration shadows below the bifurcation of the trachea in the right lung. Table 2Laboratory Data of the Two PatientsItemsPatient 1Patient 2Normal rangeWhite Blood Cells (WBC)4.83 × 103/μL12.71 × 103/μL(3.3–8.6)Neutrophils91%94%(42.4–75)Lymphocytes4.10%4.10%(18.2–47.7)Monocytes1.90%1.60%(3.3–9)Eosinophils2.30%0.20%(0.4–8.6)Basophils;0.60%0.40%(0.2–1.4)Hemoglobin16.1 g/dL14.5 g/dL(13.7–16.8)Platelet30.7 × 10 4/μL16.5 × 10 4/μL(15.8–34.8)Serum creatinine6.47 mg/dL2.37 mg/dL(0.65–1.87)Blood urea nitrogen14.3 mg/L53.0 mg/L(8–20)Aspartate aminotransferase (AST)44 U/L93 U/L(13–39)Alanine aminotransferase (ALT)31 U/L143 U/L(10–42)Creatine Kinase (CK)221 U/L471 U/L(30–170)C-reactive protein (CRP)52.0 mg/dL46.9 mg/dL(0–0.14)Procalcitonin (PCT)>100 ng/mL27.1 ng/mL(<0.05)Prothrombin time-International normalized ratio (PT-INR)1.221.14(0.85–1.15)Fibrin/fibrinogen degradation products (FDP)4.9 μg/mL15.7μg/mL(<5.0)Fibrinogen (FIB)>900 mg/dL>900 mg/dL(200–400) Laboratory Data of the Two Patients Pathogenic bacteria were not isolated from his sputum and transbronchial specimens although sputum quality was adequate due to Gram staining and leukocyte count. We could not perform respiratory PCR for atypical pathogens. We strongly suspected the pneumococcal pneumonia or legionella pneumonia, but rapid urine antigen tests for Streptococcus pneumoniae and L. pneumophila serotype 1 (BinaxNOW, Abbott, Abbott Park, IL) were both negative. However, GAS, which showed good susceptibility to antibiotics (Table 3), was isolated from his blood. This patient meet the STSS criteria,16 but not disseminated intravascular coagulation (DIC, <4 points, Table 2).17 Intensive care, including a ventilator and hemodialysis, was started immediately on admission, but he died on Day 1. Table 3Antibiotic Susceptibility of Streptococcus pyogenes Isolated from the Two PatientsPatient 1Patient 2MICS/I/RMICS/I/RPCG<=0.063S<=0.063SABPC<=0.125S<=0.125SCTX<=0.125S<=0.125SLVFX<=0.5S<=0.5SMEPM<=0.125S<=0.125SCLDM<=0.25S<=0.25SAbbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistant; PCG, penicillin G; ABPC, ampicillin; CTX, cefotaxime; LVFX, levofloxacin; MEPM, meropenem; CLDM, clindamycin; respectively. Antibiotic Susceptibility of Streptococcus pyogenes Isolated from the Two Patients Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistant; PCG, penicillin G; ABPC, ampicillin; CTX, cefotaxime; LVFX, levofloxacin; MEPM, meropenem; CLDM, clindamycin; respectively. Patient 2 A 68-year-old woman with no underlying disease was admitted to our hospital with a fever (38.1°C), mild dyspnea (SpO2 94% on room air), and general malaise (Day 0) (Table 1). She had visited an outpatient clinic, and influenza A was diagnosed by a rapid antigen test on Day −1, and laninamivir inhalation was received once. She had received the influenza vaccine for the season. On admission, her body temperature was 38.1°C, and quick SOFA score was 3/3 points. She was also in shock, with blood pressure of 76/44 mmHg, and a norepinephrine drip infusion was started, but chest radiography and computed tomography did not show obvious shadows, such as infiltration or ground-glass opacities (Figure 2). Her laboratory data showed very severe inflammation status, including CRP of 46.9 mg/dL and PCT of 27.1 ng/mL, and her WBC count was also increased (Table 2). In addition, sCr was increased, at 2.37 mg/dL, suggesting AKI. Chest X-ray and computed tomography (CT) of Patient 2 on admission (Day 0). (A): Chest X-ray, and (B): CT. This patient did not show the typical infiltration shadows and ground glass opacities, and no abnormal shadows had not been found in the follow up. Although no shadows were obvious in the lung fields, S. pneumoniae was isolated from her sputum. In addition, GAS was also isolated from her blood on admission. GAS showed good susceptibility to antibiotics (Table 3), and the isolated Sp from her sputum also showed good susceptibility to antibiotics (data not shown). STSS criteria, but not DIC (<4 points), were met as same as Patient 1 (Table 2). Intensive care, including a ventilator and hemodialysis, was started immediately in addition to a meropenem drip infusion, 0.5 g twice per day on admission. She ultimately recovered on day 10 and still survived after 30 days from the onset. Discussion Co-infections of influenza virus and bacteria have been well known as synergistic factors leading to severe inflammation, and of the Streptococcus species, S. pneumoniae and GAS are key bacteria that induce a severe inflammatory status and invasive disease, such as bacteremia, toxic shock syndrome, and pneumonia, which are associated with high mortality despite the susceptibility of the bacteria to antibiotics, including penicillin.9,18 Infection with GAS alone could induce such severe disease, but it is more frequent with influenza virus co-infection.10,19,20 In this report, two cases of co-infection with influenza and GAS bacteremia were presented. Both cases developed shock with very severe inflammation and had AKI, similar to previous reported cases, suggesting synergistic mechanisms between the virus and bacteria.10 Influenza A virus infection alone is rarely lethal, but it can promote secondary bacterial infections that are often fatal, as previously reported in not only S pneumonniae and GAS, but also Haemophilus influenzae and Staphylococcus aureus.21 In mouse studies, influenza virus infection with superinfection by other invasive types of GAS strains, but not with non-invasive types, also caused the deaths of more than 80% of mice within two weeks of GAS infection, even though non-lethal doses of influenza virus and GAS were inoculated. Superinfection by GAS in patients with influenza may be promoted by external environmental factors, such as enhancement of bacterial adhesion and invasion of host epithelial cells infected with influenza virus, pathogenic factors of influenza virus including PB1-F2 protein, and changes in protective immune responses to bacterial infection attributable to virus co-infection in host epithelial cells.10 (i) Influenza neuraminidase exposing host receptors that GAS adheres to, (ii) M-protein–fibrinogen interaction, (iii) superantigen-mediated cytokine storm (SpeA, SpeC, SmeZ), (iv) suppression of pulmonary macrophage and neutrophil function by type-I interferon might be key elements of severe influenza when GAS infected simultaneously.22,23 In addition, emm-type of GAS might be related with influenza co-infection although we could not confirm the genetic background of isolated GAS in this study.24 In the present report, both patients showed severe bacteremia and AKI, but Patient 1 who died had pneumonia, whereas Patient 2 who survived did not show massive pneumonia, although S. pneumoniae was isolated from Patient 2’s sputum. DIC was not presented in both patients, but pneumonia may be the explanation for the divergent outcomes. The immune reactions and/or degree of bacterial invasion might ultimately determine survival. In addition, subclade K type influenza infection was prevalent during this season, and this mutant strain might have attenuated the vaccine’s effectiveness against the endemic and dominant influenza virus.6,25 However, early post-vaccination, vaccine effectiveness against influenza-related emergency department attendances and hospital admissions remained within typical ranges, at 72–75% in children and adolescents (<18 years) and 32–39% in adults. Thus, vaccination remains effective against clinical disease caused by influenza A(H3N2) viruses. In fact, the younger patient who did not survive had not received the vaccination for the season, although the older patient who survived received the vaccination in the present report. Furthermore, treatment was delayed in the patient who did not survive in the present study. The patient who survived received treatment with an anti-influenza agent within one day after onset, but the other patient who did not survive received the anti-influenza agent three days after onset, although administration of anti-influenza agents is usually recommended within two days.4 In the data from the nationwide severe influenza surveillance by internet registration system, in-hospital death was recorded for 2/57 patients (3.5%) in the group treated by baloxavir (BXM) and in 30/433 (6.9%) in the non-BXM group. The characteristics of the two fatal cases in the BXM group were that they were elderly, had no history of vaccination, and received anti-influenza agents more than two days after admission without antibiotics.5 Early diagnosis and early treatment, as well as vaccination, might be critical for survival in severe cases, including co-infection of influenza virus and GAS. The IDSA recommendation of antiviral within 48 hours is well established and worth reiterating although the present cases cannot demonstrate this effect given the simultaneous differences in pathology, age, sex, and vaccination.4 Some limitations to this case series should be kept in mind when interpreting the results. First, the subclade K influenza virus and invasive GAS, including emm-type characterizations, were not confirmed by genetic analysis in the present study. Second, the sample size was small. Third, as this was a series of only two cases, statistical testing was not done, and there remain the possibilities of selection bias (since only influenza and only GAS cases were not included) and confounding by prior antibiotic use. Further study of a large sample will be needed in subclade K influenza endemic seasons for patients co-infected with influenza and GAS, and they should be compared with adult patients infected only with influenza or only with GAS. Conclusions We describe two adults with influenza A and bacteremic GAS co-infection during the 2025–2026 H3N2 subclade K-predominant season in Japan; both presented with septic shock and AKI, with divergent outcomes that may reflect the presence or absence of pneumonia and other clinical differences. Clinicians should maintain a high index of suspicion for invasive GAS in influenza patients with shock, and timely antiviral therapy and seasonal vaccination remain important. Acknowledgments The author would like to thank all healthcare staff, including physicians, pharmacists, nurses, and medical clinical microbiological technicians, for their kind support with influenza and related severe co-infection management in Saitama Medical University International Medical Center. Disclosure The author reports no conflicts of interest in this work. References